Mumbai, June 21, 2017: Pharma Major,Cadila Healthcare Ltd (Zydus Cadila) today said it has received final approval from the USFDA to market Diflunisal tablets in the strength of 500 mg.
It is a non-steroidal anti-inflammatory drug (NSAID) and will be produced at the group’s formulations manufacturing facility at Baddi, Himachal Pradesh, company said in a filing with BSE.
United News of India
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…